After a Failed IVF Cycle: What Is Worth Investigating

Usually not. A single failed transfer is a common outcome even when everything has gone well, and treating it as evidence of a hidden problem leads to investigation that finds things which were never causing anything.

ESHRE's 2023 good practice recommendations frame this in terms of odds rather than counts. The recommended threshold for the cumulative predicted chance of implantation, before starting further investigation, is 60%.

• Add up the estimated implantation chance of each embryo transferred so far.
• Below 60% cumulative, chance is the likelier explanation.
• Two transfers at 25% each is an ordinary result, not a signal.
• The old 'three failed cycles' rule is not the current definition.

Our article on recurrent implantation failure covers the 2023 definition in full and why it replaced a count of transfers.

The cycle itself, before any new tests. Most of what changes a second attempt comes from the record of the first, and it costs nothing to go through it.

• Response to stimulation — was the protocol and dose right?
• Number and quality of eggs and embryos at each stage.
• Whether the transfer itself was straightforward.
• Endometrial thickness and timing.

A clinic that reviews and adapts after a failed cycle is doing something more valuable than one that repeats the same protocol unchanged. Asking what will be different next time is a fair question and the answer should be specific.

Our comparison of antagonist and agonist protocols covers the main protocol decision and what the trials show about each.

• IVF Add-Ons: What the Randomized Trials Actually Found
• IVF Success Rates: How to Read the Numbers You Are Quoted
• Fertility Myths vs Facts: Ten Claims Checked Against the Evidence
• What Is Diminished Ovarian Reserve? What the Tests Do and Do Not Tell You (2026)
• IVF vs ICSI — What the Difference Is, and When ICSI Actually Helps (2026)
• IUI vs IVF — Which Treatment Is Right for You? (2026)
• Endometriosis and IVF: What the Evidence Says About Surgery First

A substantial amount of what is offered after repeated failure has been examined and specifically advised against. ESHRE's 2023 recommendations are unusually direct about immunological testing.

• Peripheral NK cell testing is not recommended.
• Uterine NK cell testing is not recommended.
• Uterine T lymphocyte assessment is not recommended.
• Blood cytokine assessment is not recommended.

On endometrial receptivity testing, the position is that there are insufficient data to recommend routine use of any commercially available test to diagnose the cause of recurrent implantation failure.

One test is recommended in defined circumstances: assessment of antiphospholipid antibodies and antiphospholipid syndrome, in women with additional risk factors for thrombophilia.

It is often suggested at this point, and the evidence for it as a routine response is weaker than the suggestion implies. ASRM's 2024 committee opinion states that the value of PGT-A as a routine screening test for all IVF patients has not been demonstrated.

That does not rule it out after repeated failure, which is one of the situations where the argument is strongest. It does mean it should be discussed as a decision with trade-offs rather than presented as the obvious next step.

• PGT-A selects among existing embryos; it does not create more.
• It requires a biopsy and adds cost.
• A euploid result does not guarantee implantation.
• It is more defensible after repeated failure than as a default.

Our article on PGT-A covers what the trials found, including the criticisms of them.

A proportion of repeated failure has no identified cause after full investigation. That is a genuine result and an uncomfortable one, and it is more honest than attaching a diagnosis to a test that ESHRE does not recommend.

It also does not mean the next cycle will fail. Cumulative live birth rates rise across attempts, and many people who have had failed cycles go on to conceive without anything ever being identified as the reason for the earlier ones.

• No identified cause is a common outcome, not a failure of investigation.
• Cumulative chances improve across attempts.
• Deciding how many cycles to attempt, in advance, is reasonable.
• Stopping is a legitimate decision, not a defeat.

The emotional weight of this is covered in our article on mental health, where the prevalence figures make clear how common a very hard reaction is.

There is one practical thing worth doing before the next attempt regardless of what is investigated: ask for the full cycle record, including embryology notes, in writing. If you ever seek a second opinion, that document is what the second clinician will need, and it is far easier to obtain while you are still a patient.

A second opinion is also not a betrayal of your clinic, though people often treat it as one. It is ordinary in every other area of medicine where a course of treatment is expensive, repeated and uncertain, and this is all three.